Feature | February 20, 2014

Medtronic Launches Miniaturized Cardiac Monitor

Medtronic Reveal Linq Insertable Cardiac Monitor Implantable Holter ECG Wireless
Medtronic Reveal Linq Insertable Cardiac Monitor Implantable Holter ECG Wireless

February 20, 2014 — Medtronic Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance, CE marking and the global launch of its Reveal Linq Insertable Cardiac Monitor (ICM) System. Medtronic calls it the smallest implantable cardiac monitoring device available for patients. 

The Reveal Linq ICM is approximately one-third the size of a AAA battery (~1 cc), making it more than 80 percent smaller than other ICMs. The device is part of a system that allows physicians to continuously and wirelessly monitor a patient’s heart for up to three years, with 20 percent more data memory than its larger predecessor, Reveal XT. 

The system provides remote monitoring through the CarelinkNetwork in which physicians can request notifications to alert them if their patients have cardiac events. The Reveal Linq ICM is indicated for patients who experience symptoms such as dizziness, palpitation, syncope and chest pain that may suggest a cardiac arrhythmia, and for patients at increased risk for cardiac arrhythmias.

Placed just beneath the skin through a small incision of less than 1 cm in the upper left side of the chest, the Reveal Linq ICM is often nearly invisible to the naked eye once inserted. The device is placed using a minimally invasive insertion procedure, which simplifies the experience for both physicians and their patients. The Reveal Linq ICM is MR-Conditional, allowing patients to undergo magnetic resonance imaging (MRI) if needed.

The Reveal Linq system also includes the new MyCareLink Patient Monitor. That is a simplified remote monitoring system with global cellular technology that transmits patients’ cardiac device diagnostic data to their clinicians from nearly any location in the world.

For more information: www.reveallinq.com

Related Content

Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
Sponsored Content | Videos | Business| July 13, 2017
Randall Thompson, M.D., professor of medicine at the University of Missouri, Kansas City, attending cardiologist, Mid
iRhythm and Stanford Researchers Develop Deep Learning-Based Cardiac Arrhthymia Detection Algorithm
News | Artificial Intelligence| July 11, 2017
iRhythm Technologies Inc. announced a collaboration with the Stanford Machine Learning Group that has resulted in the...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillators (ICD)| July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Medtronic Reactive ATP Therapy Slows Progression of Atrial Fibrillation in Real-World Population
News | Atrial Fibrillation| July 03, 2017
Medtronic recently announced that its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in...
Overlay Init